2025-09-15 - Analysis Report
Okay, here's a comprehensive report on UnitedHealth Group Inc. (UNH), based on the data you provided.

## UnitedHealth Group Inc. (UNH) Analysis

UnitedHealth Group Inc. is a diversified health care company that provides a wide range of health benefits and services.

### 1. Performance vs. S&P 500 (VOO)

*   **Cumulative Return (UNH):** 35.18%
*   **Cumulative Return (VOO):** 104.48%
*   **Absolute Divergence (Current):** -69.3
*   **Relative Divergence:** 20.5 (Indicates UNH is currently positioned at the 20.5th percentile relative to its historical divergence from the S&P 500.)

**Analysis:** UNH has significantly underperformed the S&P 500. The relative divergence of 20.5 suggests that this underperformance is not unprecedented within its historical range, but it's still a considerable gap.

**Alpha, Beta Analysis:**

| Year       | CAGR     | MDD      | Alpha   | Beta   | Cap(B)  |
| :---------- | :------- | :------- | :------ | :----- | :------ |
| 2015-2017  | 65.0%    | 56.6%    | 36.0%   | 0.0    | 199.7   |
| 2016-2018  | 52.0%    | 63.7%    | 34.0%   | 0.0    | 225.6   |
| 2017-2019  | 38.0%    | 63.7%    | 9.0%    | 0.3    | 266.2   |
| 2018-2020  | -21.0%   | 63.7%    | -40.0%  | 0.4    | 317.6   |
| 2019-2021  | 36.0%    | 61.0%    | -13.0%  | 0.4    | 454.8   |
| 2020-2022  | 28.0%    | 66.9%    | 26.0%   | 0.4    | 480.2   |
| 2021-2023  | 33.0%    | 67.5%    | 15.0%   | 0.4    | 476.8   |
| 2022-2024  | -31.0%   | 68.6%    | -57.0%  | 0.3    | 458.1   |
| 2023-2025  | -41.0%   | 75.7%    | -97.0%  | 0.1    | 319.3   |

**Analysis:**

*   **Alpha:** The alpha values are inconsistent, indicating periods of both outperformance and underperformance relative to the benchmark. Recent years show significantly negative alpha, highlighting recent underperformance.
*   **Beta:** Beta values are low, suggesting the stock is less sensitive to market movements compared to the S&P 500.
*   **CAGR:** The Compound Annual Growth Rate (CAGR) fluctuates, with recent periods showing negative growth.
*   **MDD:** The Maximum Drawdown (MDD) is high, indicating significant potential losses from peak to trough.
*   **Cap(B):** Market capitalization generally increased, but has decreased in the most recent period.

### 2. Recent Price Action

*   **Current Price:** 352.51
*   **Previous Close:** 353.61
*   **Price Change:** -0.31
*   **5-day Moving Average:** 344.214
*   **20-day Moving Average:** 315.4325
*   **60-day Moving Average:** 294.535

**Analysis:**  The price is currently slightly down compared to the previous close. The price is above all three moving averages (5-day, 20-day, and 60-day), suggesting an upward trend in the short to medium term. The 5-day moving average is above the 20-day moving average, which in turn is above the 60-day moving average, reinforcing the bullish trend.

### 3. Technical Indicators & Expected Return

*   **Market Risk Indicator (MRI):** 0.3233 (Low Risk)
*   **RSI:** 79.68 (Overbought)
*   **PPO:** 1.52
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34)
*   **Recent (20-day) Relative Divergence Change:** +7.0 (Short-term Increase)
*   **Expected Return:** 26.6% (Long-term, relative to S&P 500)

**Analysis:**

*   The RSI value of 79.68 indicates that the stock is currently overbought, which could suggest a potential pullback or consolidation in the near term.
*   PPO of 1.52 confirms a bullish trend.
*   The Hybrid Signal suggests buying 80% of available cash with caution due to the MRI.
*   The MRI indicates low market risk.
*   The recent increase in relative divergence suggests positive momentum for UNH compared to the S&P 500.
*   An expected return of 26.6% (over the S&P 500) for long-term investors is a positive signal.
*   The negative price change (-0.31) from the previous close is relatively small and doesn't indicate a significant issue.

### 4. Recent News & Significant Events

*   **Political Engagement:** News regarding UnitedHealth's interactions with Trump and its spending on political allies raises concerns about potential regulatory impacts and the company's lobbying efforts.
*   **Top-Performing Stock:** Being mentioned as a top-performing stock in August 2025 suggests some positive momentum in the recent past.
*   **Analyst Recommendations:** Inclusion in "Investing.com's stocks of the week" could indicate positive analyst sentiment.
*   **General Market Trends:** Mentions in articles about "dirt cheap stocks" and Warren Buffett's investments are less directly relevant but provide context about the broader market environment.

**Analysis:**  The news headlines present a mixed picture. The political news is concerning, while mentions in positive stock lists are encouraging.  Further investigation into the specifics of the political engagements and the reasons for recent outperformance is warranted.

### 4-2. Analyst Opinions

*   **Consensus:** Buy
*   **Mean Rating:** 1.96 (~Buy)
*   **Number of Opinions:** 24
*   **Target Price (avg/high/low):** 338.33 / 626.00 / 198.00

**Analysis:** The analyst consensus is generally positive, with a "Buy" rating and a mean rating indicating a buy recommendation. However, the average target price of $338.33 is *below* the current price of $352.51, suggesting analysts may believe the stock is currently overvalued. The wide range between the high and low target prices indicates uncertainty among analysts.

### 5. Recent Earnings Analysis

| Date       | EPS  | Revenue        |
| :--------- | :--- | :------------- |
| 2025-08-11 | 3.76 | 111.62 B$      |
| 2025-05-07 | 6.9  | 109.58 B$      |
| 2024-11-04 | 6.56 | 100.82 B$      |
| 2024-08-09 | 4.58 | 98.86 B$      |
| 2025-08-11 | 4.58 | 98.86 B$      |

**Analysis:** Revenue has generally been increasing, but EPS has been inconsistent. The most recent EPS (3.76) is relatively low compared to previous quarters.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
| :--------- | :--------- | :------------ |
| 2025-06-30 | $111.62B  | 17.93%        |
| 2025-03-31 | $109.58B  | 21.70%        |
| 2024-12-31 | $100.81B  | 21.14%        |
| 2024-09-30 | $100.82B  | 22.84%        |
| 2024-06-30 | $98.86B   | 22.31%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE   |
| :--------- | :--------- | :---- |
| 2025-06-30 | $94.72B  | 3.60% |
| 2025-03-31 | $95.04B  | 6.62% |
| 2024-12-31 | $92.66B  | 5.98% |
| 2024-09-30 | $94.53B  | 6.41% |
| 2024-06-30 | $89.36B   | 4.72% |

**Analysis:**

*   **Revenue:** Shows a consistent upward trend.
*   **Profit Margin:** Decreased significantly in the most recent quarter.
*   **Equity:** Relatively stable.
*   **ROE:** Decreased significantly in the most recent quarter, indicating a lower return on equity.

### 7. Overall Assessment

UnitedHealth Group (UNH) presents a mixed investment picture:

**Positives:**

*   Recent upward price trend (above moving averages).
*   Low Market Risk Indicator.
*   Positive short-term momentum (increase in relative divergence).
*   High expected return for long-term investors.
*   Consistent revenue growth.
*   Strong analyst consensus (Buy).

**Negatives:**

*   Significant underperformance compared to the S&P 500.
*   Overbought RSI, suggesting a potential pullback.
*   Political news raises concerns about regulatory risks.
*   Declining profit margins and ROE in the most recent quarter.
*   Analysts' average target price is *below* the current price.
*   Negative alpha values in recent years.

**Conclusion:**

UNH is experiencing short-term bullish momentum, but the long-term underperformance relative to the S&P 500, declining profitability metrics, and political uncertainty warrant caution. The high expected return is attractive, but potential investors should carefully weigh the risks before investing. The overbought RSI suggests waiting for a potential pullback before establishing a position. Further investigation into the reasons for the declining profit margins and ROE is crucial.
